Skip to main content

View full-text article in PMC

. 2020 Jun 8;12(11):10663–10675. doi: 10.18632/aging.103285

Table 4. Cox proportional hazard regression analysis of the effect of immune-related adverse events development on progression-free survival and overall survival.

Survival	Univariate analysis			Multivariate analysis^b
Survival	HR	95% CI	P	HR	95% CI	P
PFS
Any irAEs	0.509	0.305-0.849	0.01^a	0.521	0.309-0.877	0.014^a
Skin irAEs	0.298	0.174-0.510	<0.001^a	0.297	0.172-0.513	<0.001^a
Endocrine irAEs	0.232	0.073-0.742	0.014^a	0.269	0.083-0.874	0.029^a
Hepatobiliary irAEs	0.688	0.375-1.263	0.228
Gastrointestinal irAEs	0.939	0.347-2.544	0.902
Fatigue irAEs	0.390	0.176-0.899	0.021^a	0.410	0.181-0.927	0.032^a
IrAEs number	0.532	0.384-0.736	<0.001^a	0.547	0.389-0.769	0.001^a
irAEs grade	0.678	0.438-1.049	0.081
OS
Any irAEs	0.366	0.191-0.699	0.002^a	0.462	0.235-0.909	0.025^a
Skin irAEs	0.257	0.124-0.535	<0.001^a	0.288	0.132-0.628	0.002^a
Endocrine irAEs	0.258	0.061-1.087	0.065
Hepatobiliary irAEs	0.497	0.195-1.264	0.142
Gastrointestinal irAEs	0.806	0.217-2.991	0.747
Fatigue irAEs	0.186	0.044-0.779	0.021^a	0.252	0.085-1.092	0.065
IrAEs number	0.450	0.288-0.705	<0.001^a	0.529	0.326-0.857	0.01^a
IrAEs grade	0.514	0.293-0.903	0.021^a	0.641	0.357-1.151	0.136

Abbreviations: irAEs, immune-related adverse events; PFS, progression-free survival; OS, overall survival; HR, hazard ratio, CI, confidence interval

^a P value < 0.05

^b Covariables included metastasis stage (yes versus no), LDH levels (≤UNL versus>UNL), and liver metastases (yes versus no).